Skip to content

Maternal and offspring outcomes after treatment of hyperemesis by refeeding

Maternal and offspring outcomes after treatment of hyperemesis by refeeding - MOTHER Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43713
Enrollment
120
Registered
2013-04-03
Start date
2013-10-04
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperemesis gravidarum (HG) Nausea and vomiting in pregnancy (NVP)

Interventions

Women will be randomly allocated to either enteral tube feeding in addition to standard care or standard care (intravenous rehydration, with possibly anti-emetics, vitamins)

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Gestational age between 5+0 and 19+6 weeks Informed consent Women with singleton or multiple pregnancy Hospital admission because of hyperemesis gravidarum (the diagnosis of HG is made if excessive nausea or vomiting necessitates admission) First admission or readmission for hyperemesis gravidarum

Exclusion criteria

Exclusion criteria: Maternal age

Design outcomes

Primary

MeasureTime frame
Birth weight

Secondary

MeasureTime frame
Maternal outcome measures: PUQE score (Pregnancy Unique Quantification of Emesis and nausea) one week after randomization Questionnaires: HIS (Hyperemesis Impact of Symptoms questionnaire), NVPQoL (Nausea and Vomiting of Pregnancy Quality of Life questionnaire), EQ-5D (EuroQoL), HADS (Hospital Anxiety and Depression Scale), SF-36 (Short Form 36) Weight gain Dietary intake Urinary ketones Duration hospital stay Readmission Side-effects tube feeding and/or intravenous rehydration Neonatal outcome measures: Neonatal morbidity Gestational age at birth Prematurity SGA Placental weight Lipid spectrum cord blood Molecular outcome measures: Molecular outcomes (genetic, epigenetic, RNA and/or protein profiles) in umbilical cord blood and placental tissue that relate to cause and consequences of HG.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)